Login / Signup

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.

Yeh Chen LeeMadeleine T KingRachel L O'ConnellAnne LanceleyFlorence JolyFelix HilpertAlison DavisFelicia T RoncolatoAikou OkamotoJane BrycePaul DonnellanAmit M OzaElisabeth Avall-LundqvistJonathan S BerekJonathan A LedermannDominique BertonJalid SehouliAmanda FeeneyMarie-Christine KaminskyKatrina DiamanteMartin R StocklerMichael L Friedlandernull null
Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2022)
Over 50% of participants reported abdominal and psychological symptoms at baseline. Of those, 40% reported an improvement within 2 months of starting chemotherapy. Approximately one in six participants reported an improvement in HRQL. Symptom monitoring and supportive care is important as chemotherapy palliated less than half of symptomatic participants.
Keyphrases
  • locally advanced
  • healthcare
  • patient reported
  • papillary thyroid
  • palliative care
  • squamous cell carcinoma
  • chemotherapy induced
  • squamous cell
  • depressive symptoms
  • lymph node metastasis
  • chronic pain
  • endometrial cancer